Search

Your search keyword '"Frénel, Jean-Sébastien"' showing total 33 results
Start Over Author "Frénel, Jean-Sébastien"
33 results on '"Frénel, Jean-Sébastien"'

3. First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort

Author

Galvin, Angéline, Courtinard, Coralie, Bouteiller, Fanny, Gourgou, Sophie, Dalenc, Florence, Jacot, William, Arnedos, Monica, Bailleux, Caroline, Dieras, Véronique, Petit, Thierry, Emile, George, Dubray-Longeras, Pascale, Frenel, Jean-Sébastien, Bachelot, Thomas, Mailliez, Audrey, Brain, Etienne, Desmoulins, Isabelle, Massard, Vincent, Patsouris, Anne, Goncalves, Anthony, Grinda, Thomas, Delaloge, Suzette, and Bellera, Carine

Published
2024
Full Text
View/download PDF

4. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

Author

BIDARD, Francois-Clement, PISTILLI, Barbara, DALENC, Florence, BACHELOT, Thomas, DE LA MOTTE ROUGE, Thibault, SABATIER, Renaud, DUBOT, Coraline, FRENEL, Jean-Sébastien, FERRERO, Jean-Marc, LADOIRE, Sylvain, LEVY, Christelle, MOURET-REYNIER, Marie-Ange, HARDY-BESSARD, Anne-Claire, LORTHOLARY, Alain, GRENIER, Julien, CHAKIBA, Camille, STEFANI, Laetitia, SOULIE, Patrick, JACQUIN, Jean-Philippe, PLAZA, Jérôme Edouard, CLATOT, Florian, TEIXEIRA, Luis, D'HONDT, Véronique, VEGAS, Hélène, DERBEL, Olfa, GARNIER TIXIDRE, Claire, DELBALDO, Catherine, MOREAU, Lionel, CHENEAU, Caroline, PAITEL, Jean-François, BERNARD-MARTY, Chantal, SPAETH, Dominique, GENET, Dominique, MOULLET, Isabelle, BONICHON-LAMICHHANE, Nathalie, DEIANA, Laura, GREILSAMER, Charlotte, VENAT-BOUVET, Laurence, DELECROIX, Valérie, MELIS, Adrien, ORFEUVRE, Hubert, NGUYEN, Suzanne, LEGOUFFE, Eric, ZANNETTI, Alain, LE SCODAN, Romuald, DOHOLLOU, Nadine, DALIVOUST, Philippe, ARSENE, Olivier, MARQUES, Nathalie, PETIT, Thierry, MOLLON, Delphine, DAUBA, Jérôme, BONNIN, Nathalie, MORVAN, François, GARDNER, Miriam, MARTI, Adina, LEVACHE, Charles-Briac, LACHAIER, Emma, ACHILLE, Mihaela, VALMAR, Christophe, BOUAITA, Ryan, MEDIONI, Jacques, FOA, Cyril, DEL PIANO, Francesco, GOZY, Michel, ESCANDE, Anne, LEDUC, Nicolas, LUCAS, Brigitte, MILLE, Dominique, AMMARGUELLAT, Hanifa, NAJEM, Abeer, TROUBOUL, Fanny, BARTHELEMY, Philippe, DESCLOS, Hervé, MAYEUR, Didier, LORCHEL, Fabrice, GUINET, François, LAURENTY, Anne-Pascale, BOUDRANT, Axelle, GISSEROT, Olivier, ALLEAUME, Corinne, DE GRAMONT, Aimery, Bidard, François-Clément, Hardy-Bessard, Anne-Claire, Dalenc, Florence, Bachelot, Thomas, Pierga, Jean-Yves, de la Motte Rouge, Thibault, Sabatier, Renaud, Dubot, Coraline, Frenel, Jean-Sébastien, Ferrero, Jean Marc, Ladoire, Sylvain, Levy, Christelle, Mouret-Reynier, Marie-Ange, Lortholary, Alain, Grenier, Julien, Chakiba, Camille, Stefani, Laetitia, Plaza, Jérôme Edouard, Clatot, Florian, Teixeira, Luis, D'Hondt, Véronique, Vegas, Hélène, Derbel, Olfa, Garnier-Tixidre, Claire, Canon, Jean-Luc, Pistilli, Barbara, André, Fabrice, Arnould, Laurent, Pradines, Anne, Bièche, Ivan, Callens, Céline, Lemonnier, Jérôme, Berger, Frédérique, and Delaloge, Suzette

Published
2022
Full Text
View/download PDF

5. Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort

Author

Grinda, Thomas, Antoine, Alison, Jacot, William, Cottu, Paul-Henri, de la Motte Rouge, Thibault, Frenel, Jean-Sébastien, Mailliez, Audrey, Dalenc, Florence, Goncalves, Anthony, Clatot, Florian, Mouret Reynier, Marie-Ange, Levy, Christelle, Ferrero, Jean-Marc, Desmoulins, Isabelle, Uwer, Lionel, Petit, Thierry, Jouannaud, Christelle, Arnedos, Monica, Chevrot, Michaël, Courtinard, Coralie, Tredan, Olivier, Brain, Etienne, Pérol, David, Pistilli, Barbara, and Delaloge, Suzette

Published
2023
Full Text
View/download PDF

6. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

Author

Hurvitz, Sara A, Hegg, Roberto, Chung, Wei-Pang, Im, Seock-Ah, Jacot, William, Ganju, Vinod, Chiu, Joanne Wing Yan, Xu, Binghe, Hamilton, Erika, Madhusudan, Srinivasan, Iwata, Hiroji, Altintas, Sevilay, Henning, Jan-Willem, Curigliano, Giuseppe, Perez-Garcia, José Manuel, Kim, Sung-Bae, Petry, Vanessa, Huang, Chiun-Sheng, Li, Wei, Frenel, Jean-Sebastien, Antolin, Silvia, Yeo, Winnie, Bianchini, Giampaolo, Loi, Sherene, Tsurutani, Junji, Egorov, Anton, Liu, Yali, Cathcart, Jillian, Ashfaque, Shahid, and Cortés, Javier

Published
2023
Full Text
View/download PDF

7. Challenges in glioblastoma research: focus on the tumor microenvironment

Author

Bikfalvi, Andreas, da Costa, Cristine Alves, Avril, Tony, Barnier, Jean-Vianney, Bauchet, Luc, Brisson, Lucie, Cartron, Pierre Francois, Castel, Hélène, Chevet, Eric, Chneiweiss, Hervé, Clavreul, Anne, Constantin, Bruno, Coronas, Valérie, Daubon, Thomas, Dontenwill, Monique, Ducray, Francois, Entz-Werlé, Natacha, Figarella-Branger, Dominique, Fournier, Isabelle, Frenel, Jean-Sébastien, Gabut, Mathieu, Galli, Thierry, Gavard, Julie, Huberfeld, Gilles, Hugnot, Jean-Philippe, Idbaih, Ahmed, Junier, Marie-Pierre, Mathivet, Thomas, Menei, Philippe, Meyronet, David, Mirjolet, Céline, Morin, Fabrice, Mosser, Jean, Moyal, Elisabeth Cohen-Jonathan, Rousseau, Véronique, Salzet, Michel, Sanson, Marc, Seano, Giorgio, Tabouret, Emeline, Tchoghandjian, Aurélie, Turchi, Laurent, Vallette, Francois M., Vats, Somya, Verreault, Maité, and Virolle, Thierry

Published
2023
Full Text
View/download PDF

8. Immune landscape and TAM density in endometrial cancer: implications for immune checkpoint inhibitors efficacy

Author

Saux, Olivia Le, primary, Sabatier, Renaud, additional, Treilleux, Isabelle, additional, Renaud, Léa-Isabelle, additional, Brachet, Pierre-Emmanuel, additional, Martinez, Alejandra, additional, Frénel, Jean-Sébastien, additional, Abdeddaim, Cyril, additional, Berthet, Justine, additional, Barrin, Sarah, additional, Colombe-Vermorel, Amélie, additional, Odeyer, Laetitia, additional, Lainé, Alexandra, additional, Caux, Christophe, additional, Dubois, Bertrand, additional, and Ray-Coquard, Isabelle, additional

Published
2024
Full Text
View/download PDF

15. ADAGIO: A phase IIb, open-label, single-arm, multicenter study assessing the efficacy and safety of adavosertib (AZD1775) as treatment for recurrent or persistent uterine serous carcinoma (039)

Author

Liu, Joyce, Colombo, Nicoletta, Oza, Amit, Frenel, Jean-Sebastien, Corr, Bradley, Rubinstein, Maria, Nevadunsky, Nicole, Lheureux, Stephanie, Gaba, Lydia, Cortijo, Lucía González, Salutari, Vanda, You, Benoit, de Giorgio-Miller, Victoria, Khatun, Mahmuda, Ghiorghiu, Dana, and Oaknin, Ana

Published
2023
Full Text
View/download PDF

16. Mammary carcinoma: Comparative oncology between small animals and humans—New therapeutic tools.

Author

Frénel, Jean‐Sébastien and Nguyen, Frédérique

Subjects
*ONCOLOGY, *THERAPY dogs, *TUMOR classification, *HORMONE therapy, *COMBINED modality therapy, *DOGS, *CATS
Abstract

The poor outcomes associated with mammary carcinomas (MCs) in dogs and cats in terms of locoregional recurrence, distant metastasis and survival, highlight the need for better management of mammary cancers in small animals. By contrast, the outcomes of women with breast cancer (BC) have dramatically improved during the last 10 years, notably thanks to new therapeutic strategies. The aim of this article was to imagine what could be the future of therapy for dogs and cats with MCs if it became inspired from current practices in human BC. This article focuses on the importance of taking into account cancer stage and cancer subtypes in therapeutic plans, on locoregional treatments (surgery, radiation therapy), new developments in endocrine therapy, chemotherapy, PARP inhibitors and immunotherapy. Ideally, multimodal treatment regimens would be chosen according to cancer stage and cancer subtypes, and according to predictive factors that are still to be defined. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

18. Liste des auteurs

Author

Aumont, Maud, primary, Azria, David, additional, Bachelot, Thomas, additional, Bacqué, Marie-Frédérique, additional, Barranger, Emmanuel, additional, Bonnefoi, Hervé, additional, Bonnier, Pascal, additional, Bordes, Virginie, additional, Boulet, Bérénice, additional, Breton-Callu, Christel, additional, Campone, Mario, additional, Classe, Jean-Marc, additional, Ceugnart, Luc, additional, Charitansky, Hélène, additional, Chauvet, Marie-Pierre, additional, Clough, Krishna B., additional, Cordina-Duverger, Émilie, additional, Coudert, Bruno, additional, Coutant, Charles, additional, Croce, Sabrina, additional, Cutuli, Bruno, additional, Dalenc, Florence, additional, Debled, Marc, additional, Deghaye, Michel, additional, Delnatte, Capucine, additional, Desmoulins, Isabelle, additional, Diéras, Véronique, additional, Doutriaux-Dumoulin, Isabelle, additional, Espérou, Hélène, additional, Faure, Christelle, additional, Ferron, Stéphane, additional, Frénel, Jean-Sébastien, additional, Fumoleau, Pierre, additional, Fyad, Jean Pascal, additional, Giard, Sylvia, additional, Guénel, Pascal, additional, Guérin, Nicole, additional, Heudel, Pierre, additional, Houvenaeghel, Gilles, additional, Jézéquel, Pascal, additional, Leblanc-Onfroy, Magali, additional, Lemanski, Claire, additional, MacGrogan, Gaëtan, additional, Massabeau, Carole, additional, Mervoyer, Augustin, additional, Mery, Éliane, additional, Noguès, Catherine, additional, Nos, Claude, additional, Salabert, Laura, additional, Séradour, Brigitte, additional, Sorin, Thomas, additional, Taieb, Sophie, additional, Trédan, Olivier, additional, Treilleux, Isabelle, additional, Tunon de Lara, Christine, additional, and Vincent-Salomon, Anne, additional

Published
2016
Full Text
View/download PDF

20. Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program

Author

Bertho, Marion, primary, Fraisse, Julien, additional, Patsouris, Anne, additional, Cottu, Paul, additional, Arnedos, Monica, additional, Pérol, David, additional, Jaffré, Anne, additional, Goncalves, Anthony, additional, Lebitasy, Marie-Paule, additional, D’Hondt, Véronique, additional, Dalenc, Florence, additional, Ferrero, Jean-Marc, additional, Levy, Christelle, additional, Dabakuyo, Sandrine, additional, Rouzier, Roman, additional, Penault-Llorca, Frédérique, additional, Uwer, Lionel, additional, Eymard, Jean-Christophe, additional, Breton, Mathias, additional, Chevrot, Michaël, additional, Thureau, Sébastien, additional, Petit, Thierry, additional, Simon, Gaëtane, additional, and Frénel, Jean-Sébastien, additional

Published
2021
Full Text
View/download PDF

22. Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME)

Author

Sirieix, Junien, primary, Fraisse, Julien, additional, Mathoulin-Pelissier, Simone, additional, Leheurteur, Marianne, additional, Vanlemmens, Laurence, additional, Jouannaud, Christelle, additional, Diéras, Véronique, additional, Lévy, Christelle, additional, Ung, Mony, additional, Mouret-Reynier, Marie-Ange, additional, Petit, Thierry, additional, Coudert, Bruno, additional, Brain, Etienne, additional, Pistilli, Barbara, additional, Ferrero, Jean-Marc, additional, Goncalves, Anthony, additional, Uwer, Lionel, additional, Patsouris, Anne, additional, Tredan, Olivier, additional, Courtinard, Coralie, additional, Gourgou, Sophie, additional, and Frénel, Jean-Sébastien, additional

Published
2020
Full Text
View/download PDF

23. Paracaspase MALT1 regulates glioma cell survival by controlling endo‐lysosome homeostasis

Author

Jacobs, Kathryn A, primary, André‐Grégoire, Gwennan, additional, Maghe, Clément, additional, Thys, An, additional, Li, Ying, additional, Harford‐Wright, Elizabeth, additional, Trillet, Kilian, additional, Douanne, Tiphaine, additional, Alves Nicolau, Carolina, additional, Frénel, Jean‐Sébastien, additional, Bidère, Nicolas, additional, and Gavard, Julie, additional

Published
2019
Full Text
View/download PDF

27. Le statut KRAS n’influence pas l’efficacité de l’oxaliplatine ou de l’irinotécan, en association au bévacizumab, dans le traitement de première ligne du cancer colorectal métastatique

Author

Cabart, Mathilde, primary, Frénel, Jean-Sébastien, additional, Campion, Loïc, additional, Ramée, Jean-François, additional, Dupuis, Olivier, additional, Senellart, Hélène, additional, Hiret, Sandrine, additional, Douillard, Jean-Yves, additional, and Bennouna, Jaafar, additional

Published
2016
Full Text
View/download PDF

29. Le statut KRASn’influence pas l’efficacité de l’oxaliplatine ou de l’irinotécan, en association au bévacizumab, dans le traitement de première ligne du cancer colorectal métastatique

Author

Cabart, Mathilde, Frénel, Jean-Sébastien, Campion, Loïc, Ramée, Jean-François, Dupuis, Olivier, Senellart, Hélène, Hiret, Sandrine, Douillard, Jean-Yves, and Bennouna, Jaafar

Abstract

L’identification du statut RAS(KRASet NRAS) a modifié la prise en charge des cancers colorectaux métastatiques (CCRm). L’impact de la mutation de RASsur l’efficacité des chimiothérapies cytotoxiques n’est à ce jour pas déterminé. Certaines études rétrospectives seraient en faveur d’une plus grande efficacité de l’oxaliplatine dans les CCRm avec mutation de KRAS.

Published
2016
Full Text
View/download PDF

30. bc-GenExMiner 3.0: new mining module computes breast cancer gene expression correlation analyses.

Author

Jézéquel, Pascal, Frénel, Jean-Sébastien, Campion, Loïc, Guérin-Charbonnel, Catherine, Gouraud, Wilfried, Ricolleau, Gabriel, and Campone, Mario

Subjects
*BREAST cancer, *DATA mining, *STEROID hormones, *CANCER patients, *GENETIC regulation, *GENE expression
Abstract

We recently developed a user-friendly web-based application called bc-GenExMiner (http://bcgenex.centregauducheau.fr), which offered the possibility to evaluate prognostic informativity of genes in breast cancer by means of a 'prognostic module'. In this study, we develop a new module called 'correlation module', which includes three kinds of gene expression correlation analyses. The first one computes correlation coefficient between 2 or more (up to 10) chosen genes. The second one produces two lists of genes that are most correlated (positively and negatively) to a 'tested' gene. A gene ontology (GO) mining function is also proposed to explore GO 'biological process', 'molecular function' and 'cellular component' terms enrichment for the output lists of most correlated genes. The third one explores gene expression correlation between the 15 telomeric and 15 centromeric genes surrounding a 'tested' gene. These correlation analyses can be performed in different groups of patients: all patients (without any subtyping), in molecular subtypes (basal-like, HER2+, luminal A and luminal B) and according to oestrogen receptor status. Validation tests based on published data showed that these automatized analyses lead to results consistent with studies' conclusions. In brief, this new module has been developed to help basic researchers explore molecular mechanisms of breast cancer. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

31. Paracaspase MALT1 regulates glioma cell survival by controlling endo‐lysosome homeostasis.

Author

Jacobs, Kathryn A, André‐Grégoire, Gwennan, Maghe, Clément, Thys, An, Li, Ying, Harford‐Wright, Elizabeth, Trillet, Kilian, Douanne, Tiphaine, Alves Nicolau, Carolina, Frénel, Jean‐Sébastien, Bidère, Nicolas, and Gavard, Julie

Subjects
LYSOSOMES, GLIOBLASTOMA multiforme, BRAIN tumors, RNA-binding proteins, LYMPHOID tissue, CELL death
Abstract

Glioblastoma is one of the most lethal forms of adult cancer with a median survival of around 15 months. A potential treatment strategy involves targeting glioblastoma stem‐like cells (GSC), which constitute a cell autonomous reservoir of aberrant cells able to initiate, maintain, and repopulate the tumor mass. Here, we report that the expression of the paracaspase mucosa‐associated lymphoid tissue l (MALT1), a protease previously linked to antigen receptor‐mediated NF‐κB activation and B‐cell lymphoma survival, inversely correlates with patient probability of survival. The knockdown of MALT1 largely impaired the expansion of patient‐derived stem‐like cells in vitro, and this could be recapitulated with pharmacological inhibitors, in vitro and in vivo. Blocking MALT1 protease activity increases the endo‐lysosome abundance, impairs autophagic flux, and culminates in lysosomal‐mediated cell death, concomitantly with mTOR inactivation and dispersion from endo‐lysosomes. These findings place MALT1 as a new druggable target involved in glioblastoma and unveil ways to modulate the homeostasis of endo‐lysosomes. Synopsis: This study unveils that the paracaspase activity of MALT1, which was previously linked to antigen receptor‐mediated NF‐κB activation and lymphomas, is decisive for the expansion of glioblastoma stem‐like cells (GSC), highlighting potential therapeutic strategies against brain cancers. Expression and catalytic activity of MALT1 are required for GSC expansion.Pharmacological targeting of MALT1 is lethal to GSCs and reduces the expansion of established tumors in mice.MALT1 depletion results in an increased endo‐lysosomal compartment and decreased mTOR signaling.MALT1 expression negatively correlates to that of RNA‐binding protein Quaking to control endo‐lysosomal biogenesis. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

32. [KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer].

Author

Cabart M, Frénel JS, Campion L, Ramée JF, Dupuis O, Senellart H, Hiret S, Douillard JY, and Bennouna J

Subjects
Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Bevacizumab administration & dosage, Camptothecin administration & dosage, Camptothecin therapeutic use, Colorectal Neoplasms mortality, Colorectal Neoplasms pathology, Female, Fluorouracil administration & dosage, France, Humans, Irinotecan, Leucovorin administration & dosage, Male, Middle Aged, Organoplatinum Compounds administration & dosage, Oxaliplatin, Retrospective Studies, Survival Analysis, Antineoplastic Agents therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bevacizumab therapeutic use, Camptothecin analogs & derivatives, Colorectal Neoplasms drug therapy, Colorectal Neoplasms genetics, Genes, ras, Organoplatinum Compounds therapeutic use
Abstract

Introduction: The identification of RAS status (KRAS and NRAS) has changed the management of metastatic colorectal cancer (mCRC). The impact of the RAS mutation on cytotoxic chemotherapy efficacy has not yet been determined. Nevertheless, several retrospective studies suggest a greater efficacy of oxaliplatin in mCRC with KRAS mutation., Methods: We analyzed retrospectively the progression free survival (PFS) and overall survival (OS) in 216 patients with mCRC receiving first line treatment between 2008 and 2010 according to KRAS status and chemotherapy regimen used (oxaliplatin- or irinotecan-based, in association with fluoropyrimidine and bevacizumab)., Results: In KRAS mutated tumors, median OS was 23.4 months with oxaliplatin-based regimen, and 23.6 months with irinotecan-based regimen, with no significant difference (HR 1.30; 95 % CI 0.81-2.09; P=0.27). In KRAS wild-type tumors, median OS was 30.3 months with oxaliplatin-based regimen, and 25.4 months with irinotecan-based regimen, with no significant difference (HR 0.81; 95 % CI 0.52-1.24; P=0.33). Similarly, KRAS mutational status had no significant effect on efficacy of oxaliplatin or irinotecan regarding PFS., Discussion: In this retrospective study, KRAS mutational status does not influence the efficacy of first line cytotoxic chemotherapy in association with bevacizumab., (Copyright © 2016 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)

Published
2016
Full Text
View/download PDF

33. [The role of interval surgery in the treatment's strategy of advanced ovarian cancer].

Author

Jaffré I, Bordes V, Dejode M, Dravet F, Frénel JS, Berton-Rigaud D, and Classe JM

Subjects
Female, Humans, Neoplasm, Residual, Ovarian Neoplasms drug therapy, Ovarian Neoplasms mortality, Ovarian Neoplasms pathology, Neoadjuvant Therapy methods, Ovarian Neoplasms surgery
Abstract

The extent of cytoreductive surgery and the amount of residual disease are among the most important factors impacting the survival of women with advanced ovarian cancer. Chronology of treatment is still debating. In the French standard treatment, primary surgery remains the cornerstone and interval surgery is an option. Neoadjuvant chemotherapy followed by surgery may reduce morbidity and mortality. Nevertheless the impact of this strategy on survival is still controversial.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results